Senior Fellow/Professor, H. Lee Moffitt Cancer Center, United States
Dr. Stuart Russell Maudsley is a renowned pharmacologist with a distinguished career in receptor biology, specializing in therapeutic precision medicines targeting GPCRs (G-Protein Coupled Receptors). He is currently the Principal Investigator at the Maudsley Lab and a Senior Member at Moffitt Cancer Center. Dr. Maudsley is also a co-founder of HeptOME, focusing on aging-related diseases and metabolic dysfunction. With over two decades of research experience, he has held prominent roles including scientific advisor to the Belgian Superior Health Council, and various leadership roles at Johns Hopkins, the NIH, and VIB. His groundbreaking work includes receptor pharmacology and molecular biology studies aimed at advancing novel treatments for complex human disorders, particularly cancer and neurodegenerative diseases. His career has been recognized globally, earning numerous awards and honors for his contributions to molecular pharmacology.
Profile
Education
Dr. Stuart Russell Maudsley obtained his PhD in Pharmacology from the University of Leeds, UK, where he was awarded the Ackroyd, Brotherton & Brown Scholarship. His doctoral research focused on electrophysiological and molecular biological studies of Tachykinin receptors, marking the beginning of his illustrious career in receptor pharmacology. Prior to his PhD, Dr. Maudsley earned a First-Class B.Sc. in Pharmacology from the same institution. During his academic tenure, he engaged in advanced studies of ion channel electrophysiology and the pharmacology of the central nervous system, topics that have significantly shaped his subsequent research endeavors. His educational foundation laid the groundwork for his future contributions in both academia and the pharmaceutical industry, particularly in the development of novel therapeutic strategies for neurodegenerative diseases, cancer, and metabolic disorders.
Experience
Dr. Stuart Russell Maudsley boasts an extensive career with leadership roles across academia, industry, and government. He is the Principal Investigator at the Maudsley Lab at Moffitt Cancer Center and the co-founder of HeptOME, where he focuses on receptor-targeted therapies for aging-related metabolic diseases. Throughout his career, Dr. Maudsley has held various significant positions, including Adjunct Director at VIB, Vice-Chair at the University of Antwerpβs Department of Biomedical Science, and Principal Investigator at the NIH. He has contributed to numerous international projects, including his work as a Special Science Advisor to the Belgian Superior Health Council. Dr. Maudsley has also led scientific teams at Johnson & Johnson, the U.S. Department of Defense, and the NIH, where he made crucial contributions to drug development and the understanding of receptor pharmacology. His leadership and expertise have resulted in groundbreaking advancements in the pharmacology and therapeutics of complex diseases.
Awards and Honors
Dr. Stuart Russell Maudsley has received numerous prestigious awards and honors throughout his career. Notable recognitions include the 2021 UAntwerpen Seal of Excellence Grant, 2020 Johnson & Johnson Research Grant, and the 2019 FWO Doctoral Research Grant. He has also been honored with the FWO Senior Research Fellows Grant and the UAntwerpen-IOF Industrial Collaboration Research Grant in 2019. His work in molecular pharmacology and receptor biology has led to the receipt of multiple awards from both European and American institutions, including the National Institutes of Health On-the-Spot Award (2011-2013). Dr. Maudsleyβs groundbreaking research on neurodegenerative diseases, aging, and metabolic dysfunction has earned him widespread recognition in the scientific community. His scientific excellence and contributions to pharmacology, drug discovery, and biotechnology continue to inspire advancements in the treatment of complex human disorders.
Research Focus
Dr. Stuart Russell Maudsley’s research primarily focuses on receptor pharmacology, with a special emphasis on G-Protein Coupled Receptors (GPCRs) and their role in human disease. His work seeks to identify and develop precision GPCR-targeted therapies for cancer, neurodegenerative disorders, and metabolic diseases such as obesity and aging-related conditions. Through his leadership in both academic labs and the biotech industry, Dr. Maudsley investigates novel biotechnological platforms, including both wet and dry biomedical technologies. He aims to create multidimensional precision medicines that can more effectively treat complex disorders, particularly those related to aging. His current research in the Maudsley Lab centers on the molecular mechanisms that underlie aging and neurodegenerative diseases, as well as the identification of potential therapeutic agents. By exploring the intricate signaling pathways of GPCRs, Dr. Maudsley is paving the way for the development of innovative treatments for diseases that currently lack effective therapies.
Publications Top Notes
- Ξ²-Arrestin-dependent formation of Ξ²2 adrenergic receptor-Src protein kinase complexes β Science (1999) π§¬π
- BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders β Trends in Neurosciences (2004) π§
- The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women β International Journal of Obesity (2011) ππββοΈ
- Gonadotropin-releasing hormone receptors β Endocrine Reviews (2004) ππ¬
- Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma β Free Radical Biology and Medicine (2007) π₯
- Caloric restriction and intermittent fasting: two potential diets for successful brain aging β Ageing Research Reviews (2006) π§
- The Ξ²2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor β Journal of Biological Chemistry (2000) π§¬π¬